Clinical trials: Multi-System-Atrophy
Multiple Sclerosis
Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate
Rates of brain atrophy for long term users of fingolimod when compared to glatiramer acetate have not been examined in patients with relapsing forms of multiple sclerosis (MS).
- Trial name
- NCT02307877
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Colorado, Denver
Wolfram Syndrome
Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome
Open label, phase II study non randomized single group assignment of 20 evaluable patients 13 years and older, over 37,5 kg body-weight, with sensorineural hearing loss of at least 20 dB at 8 kHz in high frequency average (HFA)…
- Trial name
- AUDIOWOLF (NCT04940572)
- Testing
- Depakine
- Where
- 2 sites in France, Spain
- Volunteers
- 23 people
- Sponsor
- Centre d'Etude des Cellules Souches
Cachexia; Cancer; Sarcopenia
Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics
Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can…
- Trial name
- PRCC-MO (NCT07519837)
- Testing
- Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients, Standard nutritional intervention was administered as a positive control to validate experimental efficacy.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- China Medical University, China
Alzheimer Disease, Parkinson Disease
hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
To evaluate the safety and preliminary efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles hUC-MSC-sEV-001 nasal drops in multiple neurodegenerative diseases, including Alzheimer's disease…
- Conditions
- Alzheimer Disease, Parkinson Disease, Lewy Body Dementia, Multiple System Atrophy
- Trial name
- NCT06607900
- Testing
- hUC-MSC-sEV-001 nasal drops
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xuanwu Hospital, Beijing
Autonomic Failure, Pure Autonomic Failure
[18F]F-DOPA Imaging in Patients With Autonomic Failure
Alpha-synucleinopathies refer to age-related neurodegenerative and dementing disorders, characterized by the accumulation of alpha-synuclein in neurons and/or glia.
- Conditions
- Autonomic Failure, Pure Autonomic Failure, Parkinson Disease, Multiple System Atrophy
- Trial name
- NCT04246437
- Testing
- [18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Daniel Claassen
Myotonic Dystrophy 1
Home-based Training and Supplementation in DM1 Patients
Myotonic dystrophy type 1 (DM1) is a rare genetic disease that affects about 1 in 2100 people. Patients diagnosed with DM1 present with many symptoms, however, their muscles are mainly affected.
- Trial name
- DM1HBET (NCT05848830)
- Testing
- Mult-ingredient supplement, Concurrent exercise training
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- McMaster University
Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic
Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
This study is aimed at patients with multi-system atrophy - parkinsonian type (P-MSA) or Parkinson's disease (PD) receiving dopaminergic drugs and suffering from orthostatic hypotension (OH).
- Conditions
- Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic, Parkinson Disease
- Trial name
- CARBIDOH (NCT06831500)
- Testing
- Administration of Carbidopa/levodopa
- Where
- 2 sites in Switzerland
- Volunteers
- 36 people
- Sponsor
- Julien Bally
Multiple System Atrophy
Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare and aggressive neurodegenerative disorder characterized by a combination of motor impairments, autonomic dysfunction, and cerebellar ataxia, with no currently available disease-modifying…
- Trial name
- NCT07036939
- Testing
- Immediate LVA, Delayed LVA
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Military Operational Stress Reaction, Malnutrition (Calorie)
Physiological Response to Protein and Energy-enhanced Food Products During Winter Military Training
Soldiers commonly lose muscle mass during training and combat operations that produce large energy deficits (i.e., calories burned > calories consumed).
- Conditions
- Military Operational Stress Reaction, Malnutrition (Calorie), Weight Loss, Muscle Wasting
- Trial name
- NCT05210205
- Testing
- EAA, Energy Dense, Control
- Where
- Norway
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- United States Army Research Institute of Environmental Medicine
Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Efficacy and Safety of Transcranial dIrect Current stiMulation in Multiple System Atrophy-Cerebellar Variant
This is a double-blind, randomized, sham-controlled clinical trial that aim to verify the safety and the efficacy of anodal transcranial direct current stimulation (tDCS) cerebellar symptoms in Multiple System Atrophy type C…
- Trial name
- STIM-MSA (NCT06821256)
- Testing
- Anodal transcranial direct current stimulation (a-tDCS)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Salerno
Prader Labhart Willi Syndrome, Body Weight Changes
Prader-Willi Syndrome Body Composition
Adults aged over 18 years, with the diagnosis of Prader-willi syndrome will be recruited through the hospital's outpatient clinic for either as intervention group receiving therapeutic elastic band training, or as control group…
- Conditions
- Prader Labhart Willi Syndrome, Body Weight Changes, Sarcopenia
- Trial name
- NCT04597645
- Testing
- Therapeutic elastic band resistance training
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Muscular Dystrophies
A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration
The purpose of the extension phase of this study is to determine whether Drisapersen is effective in the treatment of boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.
- Trial name
- NCT01910649
- Testing
- Drisapersen
- Volunteers
- 12 people
- Sponsor
- BioMarin Pharmaceutical
Sarcopenia
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in patients with sarcopenia.
- Trial name
- NCT01963598
- Testing
- REGN1033 (SAR391786)
- Where
- 43 sites in United States, France and 2 more
- Volunteers
- 253 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple System Atrophy
Exenatide Once-weekly as a Treatment for Multiple System Atrophy
Fifty patients with early stage Multiple System Atrophy (MSA) will be recruited and randomised to receive Exenatide injections, or to act as controls in this open label trial.
- Trial name
- MSA (NCT04431713)
- Testing
- Exenatide Pen Injector [Bydureon]
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Myotonic Dystrophy 1
Study of ATX-01 in Participants With DM1
The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated.
- Trial name
- ArthemiR (NCT06300307)
- Testing
- ATX-01
- Where
- 12 sites in United States, Canada and 5 more
- Volunteers
- 56 people
- Sponsor
- ARTHEx Biotech S.L.
MSA - Multiple System Atrophy, MSA
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism…
- Trial name
- NCT07465198
- Testing
- MSCs
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Biocells Medical
Duchenne Muscular Dystrophy
A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)
This Phase II study is an open-label, multiple dose study to evaluate the safety, tolerability, PK, PD, clinical efficacy, behavior and neuropsychology, and physical functioning vamorolone over a treatment period of 12 weeks in…
- Trial name
- NCT05185622
- Testing
- Vamorolone
- Where
- 5 sites in Canada
- Volunteers
- 54 people
- Sponsor
- Santhera Pharmaceuticals
Orthostatic Hypotension, Pure Autonomic Failure
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
The autonomic or automatic nervous system helps control blood pressure. Diseases of the autonomic nervous system may result in a drop in blood pressure on standing in many cases leading to fainting.
- Conditions
- Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease
- Trial name
- 6103 (NCT01316666)
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University Medical Center
Muscle Weakness, Atrophy, Muscle
Muscle Stem Cell Quality in Atrophy
The goal of this clinical trial is to compare the quality of mesoangioblasts isolated from various patient groups suffering from muscle atrophy.
- Conditions
- Muscle Weakness, Atrophy, Muscle, Cachexia, Sarcopenia
- Trial name
- ATROMAB (NCT06077734)
- Testing
- In vitro analyse
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Maastricht University Medical Center